Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3K$\delta$/$\gamma$ inhibitor RP6530.
Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3K$\delta$/$\gamma$ inhibitor RP6530.